REG - Trellus Health PLC - Pfizer Licensing Agreement Renewal

Trellus HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM1569Aa&default-theme=true

RNS Number : 1569A  Trellus Health PLC  13 April 2026

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Pfizer Licensing Agreement Renewal

 

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus
Elevate®, a digital platform that integrates data analytics with
personalised, scientifically proven resilience programmes and value-based
solutions to manage complex chronic conditions, is pleased to announce that it
has signed a renewal of its Licensing Agreement with Pfizer Inc. ("Pfizer").

 

Under the renewed agreement, Pfizer will continue to license Trellus Health's
patient support educational content for inclusion within its inflammatory
bowel disease ("IBD") digital application. The original agreement was entered
into in the second quarter of 2024.

 

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "We are
excited to extend this agreement with Pfizer, which underscores both the
continued engagement of their users with our content on the platform and the
value of our resilience-driven approach and methodology. Alongside our recent
Gastro Health Master Services Agreement, the extension of our collaboration
with Johnson & Johnson, and the continued roll-out of TrialSet™ across
clinical trials, this renewal further supports the applicability of our
platform across the pharmaceutical lifecycle. We remain focused on advancing
commercial discussions and converting pipeline opportunities into revenue."

 

As previously announced, the Company has reduced its monthly cash burn to an
average of c. $300k as of March 2026. With this renewal, as well as a loan
from Laurie Keefer, Ph.D.,the Company's scientific co-founder and co-inventor
of the Company's resilience methodology, the Company expects its cash runway
to extend into May 2026.

 

The Board remains supportive of the Company's commercial strategy and is
engaged in ongoing discussions regarding a range of potential funding options
to further extend the Company's cash runway.

 

 

Enquiries:

 

 Trellus Health plc                                                                         https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder                                Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)
 Philip Davies / Jalini Kalaravy / Samed Ethemi      Tel: +44 (0)20 7496 3000

 Walbrook PR                           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                           (mailto:trellus@walbrookpr.com)
 Lianne Applegarth /                                                                      Mob: +44 (0)7584 391 303/
 Alice Woodings                                                                                                             +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

 

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRAKBBDBBKBFQD



            Copyright 2019 Regulatory News Service, all rights reserved